Vectura Group Plc (VEGPF) 1.9900 $VEGPF
Vectura and Propeller Health announce collaboration to develop digitally-connected inhalers to address chronic respiratory diseases
PR Newswire - Tue May 24, 5:00AM CDT
Vectura Group plc (LSE: VEC) and Propeller Health, the leading digital health solution for respiratory medicine, today announced a collaboration to develop inhalers that combine Vectura's proven dry powder inhaler ("DPI"
technology with Propeller's FDA-cleared digital health platform.
VEC: 32.06 (+1.08), SFE: 14.11 (+0.48)
Global Hypertension Pipeline Review 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/vln7pk/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertensionand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HypertensionOverview - Therapeutics Development - Pipeline Products for Hypertension - Overview - Pipeline Products for Hypertension - Comparative Analysis - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Carolus Therapeutics, Inc. - Cellceutix Corporation - DiaMedica Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Innopharmax Inc. - Insmed Incorporated - IntelGenx Corp. - Intercept Pharmaceuticals, Inc. - Ionis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - JW Pharmaceutical Corporation - Kowa Company, Ltd. - Lacer, S.A. - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Novartis AG - Noxamet Ltd - Omeros Corporation - Ono Pharmaceutical Co., Ltd. - Peloton Therapeutics, Inc. - Pfizer Inc. - Sihuan Pharmaceutical Holdings Group Ltd. - Silence Therapeutics Plc - VBS Pharmaceuticals - Vectura Group Plc - VG Life Sciences, Inc. - Vicore Pharma AB - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/vl...pertension
INSM: 11.73 (-0.03), PFE: 35.44 (+0.29), OMER: 12.50 (+0.28), ICPT: 162.27 (-0.94), ABBV: 66.54 (+0.44), IONS: 36.12 (-0.51), NVS: 83.12 (+0.22)
Vectura Group plc - Product Pipeline Review - 2014
M2 - Fri Jun 12, 4:48AM CDT
Pulmonary Hypertension - Pipeline Review, H1 2015
M2 - Tue Jun 09, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n7z25d/pulmonary) has announced the addition of the "Pulmonary Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Biolab Sanus Farmaceutica Ltda. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celladon Corporation - Celsion Corporation - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Eli Lilly and Company - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Ikaria Inc. - Insmed Incorporated - Ironwood Pharmaceuticals, Inc. - Lacer, S.A. - Longevity Biotech, Inc - LTT Bio-Pharma Co., Ltd. - Novartis AG - PhaseBio Pharmaceuticals, Inc. - Pluristem Therapeutics Inc. - Proteo, Inc. - Reata Pharmaceuticals, Inc. - RegeneRx Biopharmaceuticals, Inc. - Therametrics holding AG - Toray Industries, Inc. - United Therapeutics Corporation - Vectura Group plc - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/n7z25d/pulmonary
CYTK: 12.12 (+0.26), INSM: 11.73 (-0.03), PSTI: 1.51 (unch), UTHR: 125.27 (-0.21), CLDN: 1.15 (-0.02), LLY: 81.56 (-0.86), CLSN: 1.23 (+0.01), ASND: 14.45 (+0.04), IRWD: 13.39 (-0.77), GILD: 80.41 (+0.64), ARNA: 1.74 (+0.03), NVS: 83.12 (+0.22)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 315.96 (+1.40), PSTI: 1.51 (unch), ASPX: 100.96 (unch), LPTN: 2.05 (+0.01), IBIO: 0.69 (unch), FGEN: 19.90 (+0.16), AQXP: 8.97 (-0.64), GALT: 2.05 (+0.05), LLY: 81.56 (-0.86), BMY: 63.28 (-12.04), GSK: 44.89 (-0.19), GILD: 80.41 (+0.64), CGEN: 6.77 (+0.08), FPRX: 52.44 (+0.85), CELGZ: 1.11 (+0.01)
Mettrum Health Announces New Director Appointment and Grant of Options
Marketwired - Tue Jan 06, 7:03AM CST
Mettrum Health Corp. ("Mettrum" or "the Company" (TSX VENTURE: MT) (TSX VENTURE: MT.WT), a vertically integrated agri-pharmaceutical company focused on research, development, production and distribution of medical cannabis products, is pleased to announce the appointment of Mr. Jack Cashman to the Board of Directors of the Company.
MT.VN: 3.170 (+0.120)
Vectura and Propeller Health announce collaboration to develop digitally-connected inhalers to address chronic respiratory diseases
PR Newswire - Tue May 24, 5:00AM CDT
Vectura Group plc (LSE: VEC) and Propeller Health, the leading digital health solution for respiratory medicine, today announced a collaboration to develop inhalers that combine Vectura's proven dry powder inhaler ("DPI"
technology with Propeller's FDA-cleared digital health platform. VEC: 32.06 (+1.08), SFE: 14.11 (+0.48)
Global Hypertension Pipeline Review 2015
M2 - Tue Feb 09, 10:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/vln7pk/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertensionand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - HypertensionOverview - Therapeutics Development - Pipeline Products for Hypertension - Overview - Pipeline Products for Hypertension - Comparative Analysis - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Carolus Therapeutics, Inc. - Cellceutix Corporation - DiaMedica Inc. - Hanmi Pharmaceuticals, Co. Ltd. - Innopharmax Inc. - Insmed Incorporated - IntelGenx Corp. - Intercept Pharmaceuticals, Inc. - Ionis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Jiangsu Hengrui Medicine Co., Ltd. - JW Pharmaceutical Corporation - Kowa Company, Ltd. - Lacer, S.A. - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Novartis AG - Noxamet Ltd - Omeros Corporation - Ono Pharmaceutical Co., Ltd. - Peloton Therapeutics, Inc. - Pfizer Inc. - Sihuan Pharmaceutical Holdings Group Ltd. - Silence Therapeutics Plc - VBS Pharmaceuticals - Vectura Group Plc - VG Life Sciences, Inc. - Vicore Pharma AB - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/vl...pertension
INSM: 11.73 (-0.03), PFE: 35.44 (+0.29), OMER: 12.50 (+0.28), ICPT: 162.27 (-0.94), ABBV: 66.54 (+0.44), IONS: 36.12 (-0.51), NVS: 83.12 (+0.22)
Vectura Group plc - Product Pipeline Review - 2014
M2 - Fri Jun 12, 4:48AM CDT
Pulmonary Hypertension - Pipeline Review, H1 2015
M2 - Tue Jun 09, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n7z25d/pulmonary) has announced the addition of the "Pulmonary Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Biolab Sanus Farmaceutica Ltda. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celladon Corporation - Celsion Corporation - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Eli Lilly and Company - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - Hanmi Pharmaceuticals, Co. Ltd. - Ikaria Inc. - Insmed Incorporated - Ironwood Pharmaceuticals, Inc. - Lacer, S.A. - Longevity Biotech, Inc - LTT Bio-Pharma Co., Ltd. - Novartis AG - PhaseBio Pharmaceuticals, Inc. - Pluristem Therapeutics Inc. - Proteo, Inc. - Reata Pharmaceuticals, Inc. - RegeneRx Biopharmaceuticals, Inc. - Therametrics holding AG - Toray Industries, Inc. - United Therapeutics Corporation - Vectura Group plc - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/n7z25d/pulmonary
CYTK: 12.12 (+0.26), INSM: 11.73 (-0.03), PSTI: 1.51 (unch), UTHR: 125.27 (-0.21), CLDN: 1.15 (-0.02), LLY: 81.56 (-0.86), CLSN: 1.23 (+0.01), ASND: 14.45 (+0.04), IRWD: 13.39 (-0.77), GILD: 80.41 (+0.64), ARNA: 1.74 (+0.03), NVS: 83.12 (+0.22)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 315.96 (+1.40), PSTI: 1.51 (unch), ASPX: 100.96 (unch), LPTN: 2.05 (+0.01), IBIO: 0.69 (unch), FGEN: 19.90 (+0.16), AQXP: 8.97 (-0.64), GALT: 2.05 (+0.05), LLY: 81.56 (-0.86), BMY: 63.28 (-12.04), GSK: 44.89 (-0.19), GILD: 80.41 (+0.64), CGEN: 6.77 (+0.08), FPRX: 52.44 (+0.85), CELGZ: 1.11 (+0.01)
Mettrum Health Announces New Director Appointment and Grant of Options
Marketwired - Tue Jan 06, 7:03AM CST
Mettrum Health Corp. ("Mettrum" or "the Company"
(TSX VENTURE: MT) (TSX VENTURE: MT.WT), a vertically integrated agri-pharmaceutical company focused on research, development, production and distribution of medical cannabis products, is pleased to announce the appointment of Mr. Jack Cashman to the Board of Directors of the Company. MT.VN: 3.170 (+0.120)
